The conventional frame targets amyloid plaques as the cause of Alzheimer’s. The structural lens asks: what if the plaques are debris from a process, not the cause of a disease? The drugs removed the plaques and the patients did not improve. The structural lens reframes the research question: identify what produces the plaques rather than removing the plaques — find the silting process rather than dredging the silt. The collision partners are river ecologists (who understand that removing silt without addressing the upstream erosion is a temporary fix) and waste management engineers who distinguish between removing waste and addressing the process that generates it.
Circle (Tier 2): Amyloid hypothesis dominates -> funding flows to amyloid research -> amyloid researchers become peer reviewers and grant committees -> alternative hypotheses reviewed by amyloid-trained reviewers -> alternatives underfunded -> evidence base becomes disproportionately amyloid-focused -> confirms amyloid dominance -> more funding -> trials fail clinically -> failure produces calls for “better” amyloid approaches, not different hypotheses.
Chain: Amyloid plaques found -> hypothesis becomes dominant -> funding flows there -> amyloid researchers control peer review and grants -> alternatives underfunded/underpublished -> evidence base confirms dominance -> more funding -> clinical trials fail -> institutional momentum too large to redirect
For twenty-five years, the brightest minds in neuroscience aimed at the same target: the amyloid plaques in the brains of Alzheimer’s patients. The plaques were there. They correlated with the disease. The logic was direct — remove the plaques, cure the disease. Billions of dollars were invested. Dozens of clinical trials were run. The drugs worked. The plaques were removed.
The patients did not improve.
The plaques are gone and the disease continues. The most expensive, most focused, most sustained research effort in the history of neurodegenerative disease produced drugs that hit their target perfectly and missed the disease entirely.
Something in the river produced the silt. They dredged the silt. The river is still silting.
The amyloid hypothesis has dominated Alzheimer’s research since the early 1990s. The evidence was compelling: amyloid plaques accumulate in Alzheimer’s brains, genetic mutations that increase amyloid production increase Alzheimer’s risk, and the plaques precede the clinical symptoms by years. The logic: amyloid is the cause; remove amyloid, cure the disease.
Anti-amyloid therapies (aducanumab, lecanemab, donanemab) have now demonstrated the ability to significantly reduce amyloid plaques. The plaque reduction is real and measurable. The clinical benefit has been modest at best — small, statistically significant slowing of decline that many clinicians consider clinically insignificant. The plaques are gone. The cognition is not restored.
The field is in what Thomas Kuhn would call a crisis period. The dominant paradigm has been tested to destruction. The anomalies (plaque removal without clinical benefit) are accumulating. Alternative hypotheses — tau pathology, neuroinflammation, vascular insufficiency, glymphatic dysfunction, metabolic failure, microbial infection — are proliferating. The field is searching for the next paradigm.
The plaques might be the SEDIMENT, not the blockage.
The brain is a communication network. Neurons communicate through synapses. The communication requires metabolic support (glucose and oxygen delivered through blood vessels), waste clearance (metabolic byproducts removed through the glymphatic system, primarily during sleep), and structural maintenance (the synaptic connections physically maintained and pruned).
If the communication infrastructure degrades — if the blood supply diminishes, if the waste clearance slows, if the maintenance fails — debris accumulates. The debris is real. The debris includes amyloid. But the debris is the CONSEQUENCE of the infrastructure degradation, not the cause.
Dredging a silted river removes the silt. It does not fix the flow problem that produced the silt. If the flow is degraded, the silt will return.
This reframe explains the clinical trial results. Anti-amyloid therapies remove the silt. Effectively, reliably, measurably. But the flow is still degraded. The infrastructure that was failing before the dredging is still failing after. New silt accumulates. The disease progresses.
The framework redirects the research question: what is degrading the infrastructure?
The leading candidates map onto infrastructure failures:
Vascular insufficiency. The brain’s blood supply deteriorates with age, hypertension, diabetes, and atherosclerosis. Reduced blood flow means reduced metabolic support for neural communication. The neurons are not dead — they are underfunded. The communication degrades because the infrastructure that supports it is failing.
Glymphatic dysfunction. The brain’s waste clearance system operates primarily during deep sleep. The glymphatic system flushes metabolic waste — including amyloid — through channels that open during sleep and close during waking. Chronic sleep disruption impairs glymphatic clearance. The waste accumulates not because it’s produced in excess but because it’s not being removed. The plumbing is clogged.
Neuroinflammation. The brain’s immune cells (microglia) become chronically activated, producing inflammation that damages the neural communication network. The inflammation is the immune system’s response to the accumulating debris — creating a vicious cycle where debris triggers inflammation that damages the infrastructure that produces more debris.
Each of these is upstream of the plaques. Each would produce plaque accumulation as a downstream consequence. And each generates a different treatment strategy than plaque removal:
Vascular: improve cerebral blood flow (exercise, blood pressure management, diabetes control). Glymphatic: improve sleep quality (sleep intervention as Alzheimer’s prevention). Inflammatory: reduce neuroinflammation (without suppressing the immune system broadly).
The prediction: interventions targeting the INFRASTRUCTURE (blood flow, sleep quality, inflammation) will outperform interventions targeting the DEBRIS (plaques) — because the infrastructure is the cause and the debris is the consequence.
| Factor | Score | Justification |
|---|---|---|
| F1: Mortality & Irreversibility | 10 | Alzheimer’s is fatal; 6th leading cause of death in the US; neuronal loss is irreversible |
| F2: Scale | 8 | 55 million people worldwide; projected to triple by 2050 |
| F3: Compression Depth | 9 | The disease progressively compresses consciousness to its minimum — loss of memory, recognition, identity, autonomy |
| F4: Time Sensitivity | 8 | The amyloid hypothesis is losing dominance NOW; the field’s next direction is being decided in this decade |
| F5: Voice Deficit | 5 | Alzheimer’s has significant advocacy infrastructure |
| F6: Proximity Gap | 6 | Plumbers, civil engineers, and water management specialists are not at the neuroscience table — but sleep researchers increasingly are |
| F7: Temporal Displacement | 5 | Infrastructure degradation begins decades before symptoms; by the time the disease is diagnosed, the damage is extensive |
| F8: Normalization | 5 | “We’re still looking for the cause” normalizes the impasse |
| F9: Hallway Dependency | 7 | The infrastructure reframe requires vascular medicine + sleep science + immunology + neuroscience in conversation |
| F10: Knowledge Readiness | 7 | Each upstream candidate has supporting evidence; the integration is the gap |
| F11: Entry Cost | 6 | Lifestyle interventions (exercise, sleep optimization, blood pressure) are available now; targeted research requires funding redirection |
| F12: Cascade Potential | 7 | The debris-vs-infrastructure distinction applies to other neurodegenerative diseases and potentially to atherosclerosis |
Hiddenness Score: 39.4 Actionability Score: 51
Civil engineers and water management specialists understand silting. A river silts because the flow is degraded — reduced velocity allows sediment to settle. Dredging removes the sediment but does not restore the velocity. The silt returns. The specific transferable knowledge: the diagnostic protocol for a silting river is to assess FLOW first, not sediment. Measure the velocity, the volume, the upstream conditions. The sediment is the symptom. The flow is the diagnosis. Applied to Alzheimer’s: measure cerebral blood flow, glymphatic clearance rate, and metabolic support before measuring plaque load. If the flow is degraded, plaque removal is dredging.
Sleep researchers are increasingly at the table, and their findings support the infrastructure model. Chronic poor sleep impairs glymphatic clearance, and epidemiological data links sleep disruption to Alzheimer’s risk. The specific transferable knowledge: sleep is not just rest — it is MAINTENANCE. The brain’s waste clearance system runs during deep sleep the way a city’s street-cleaning runs at night. Disrupting sleep disrupts maintenance. Disrupting maintenance produces debris. The debris is a maintenance failure, not a production problem.
If you are a clinician treating patients at risk for Alzheimer’s: the three most evidence-supported upstream interventions — exercise (improves cerebral blood flow), sleep optimization (supports glymphatic clearance), and blood pressure management (maintains vascular integrity) — are available now, cost nothing beyond clinical attention, and address the infrastructure rather than the debris. They do not replace pharmacological research. They address the thing the pharmacological research has not.
If you are an Alzheimer’s researcher: consider a study design where the primary endpoint is not plaque burden but FLOW — cerebral blood flow velocity, glymphatic clearance rate, or metabolic support metrics. If an intervention improves flow without reducing plaques, does cognition improve? If an intervention reduces plaques without improving flow, does it? The comparison would test the infrastructure hypothesis directly.
Tier 2 — The hypothesis reproduces itself through the funding structure.
Amyloid hypothesis dominates → funding flows to amyloid research → amyloid researchers become reviewers and grant committees → alternative hypotheses underfunded → evidence base becomes disproportionately amyloid → dominance confirmed → more funding
The circle begins with a reasonable scientific consensus. Amyloid plaques were found in Alzheimer’s brains. The correlation was strong. The genetic evidence pointed the same direction. The hypothesis was compelling, and in the 1990s, the field converged on it. Funding agencies directed resources toward amyloid research. The researchers who received the funding produced results, published papers, trained students, and advanced through the ranks to become the senior scientists who sit on grant review committees and journal editorial boards. This is how science normally works. It is also how a hypothesis can become self-perpetuating independent of its accuracy.
A researcher submitting a grant proposal for a vascular hypothesis of Alzheimer’s sends it to a review committee staffed by amyloid researchers. The reviewers are not hostile — they are experts evaluating a proposal outside their frame. The vascular approach seems speculative to them. The preliminary data is thin (because the vascular hypothesis has received a fraction of the funding needed to generate preliminary data). The proposal is scored lower than the amyloid proposals, whose preliminary data is robust (because those hypotheses have been funded for decades). The decision is defensible at every step. The cumulative effect is that the evidence base for amyloid grows while the evidence base for alternatives remains thin, which makes amyloid look increasingly confirmed and alternatives look increasingly speculative.
When the amyloid-targeted clinical trials failed — when the plaques were removed and the patients did not improve — the circle’s self-sealing property became visible. The failure did not produce a redirection toward alternative hypotheses. It produced calls for “better” amyloid approaches: target amyloid earlier, target different forms of amyloid, combine amyloid removal with other interventions. The hypothesis absorbed its own refutation. The institutional mass — the careers, the labs, the funding streams, the expertise — was too large to redirect in response to clinical evidence. The river continued flowing in the channel decades of funding had carved.
What breaks it is funding mechanisms that evaluate infrastructure-upstream hypotheses — vascular, glymphatic, inflammatory — independently of the amyloid-dominated review process. This means review panels that include vascular physiologists, sleep researchers, and immunologists who can evaluate alternative proposals on their own terms rather than through the amyloid frame. The knowledge to redirect exists. The clinical trial evidence demands it. The barrier is that the institutions controlling the funding were built by the hypothesis they would need to question.